Health Care & Life Sciences » Biotechnology | Panacos Pharmaceuticals Inc.

Panacos Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Cash & Short Term Investments
476.50
4,879.30
87,138.00
60,766.00
51,895.00
Total Accounts Receivable
143.50
279.70
389.00
66.00
147.00
Other Current Assets
57.50
62.50
1,085.00
2,145.00
1,056.00
Total Current Assets
677.50
5,221.50
88,612.00
62,977.00
53,098.00
Net Property, Plant & Equipment
345.20
309.60
2,354.00
2,122.00
1,045.00
Total Investments and Advances
125.00
125.00
545.00
494.00
494.00
Long-Term Note Receivable
69.20
675.00
-
-
-
Other Assets
-
-
60.00
60.00
1,073.00
Total Assets
1,216.90
6,331.00
91,571.00
65,653.00
55,710.00
ST Debt & Current Portion LT Debt
3,130.30
129.30
213.00
361.00
416.00
Accounts Payable
645.40
2,288.70
1,912.00
3,226.00
2,977.00
Other Current Liabilities
342.80
325.30
3,695.00
2,923.00
3,951.00
Total Current Liabilities
4,118.50
2,743.40
5,820.00
6,510.00
7,344.00
Long-Term Debt
164.50
35.10
-
-
18,895.00
Other Liabilities
83.50
102.70
150.00
459.00
601.00
Total Liabilities
4,366.50
2,881.20
5,970.00
6,969.00
26,840.00
Common Equity (Total)
13,041.70
26,821.20
85,601.00
58,684.00
28,870.00
Total Shareholders' Equity
3,149.60
3,449.80
85,601.00
58,684.00
28,870.00
Total Equity
3,149.60
3,449.80
85,601.00
58,684.00
28,870.00
Liabilities & Shareholders' Equity
1,216.90
6,331.00
91,571.00
65,653.00
55,710.00
Preferred Stock (Carrying Value)
9,892.20
30,271.00
-
-
-

About Panacos Pharmaceuticals

View Profile
Address
134 Coolidge Avenue
Watertown Massachusetts 02472
United States
Employees -
Website http://www.panacos.com
Updated 07/08/2019
Panacos Pharmaceuticals, Inc. is a development stage company engaged in the discovery and development of small-molecule oral drug which is designed to treat Human Immunodeficiency Virus and other major human viral diseases. Its primary product is Bevirimat which is an oral human immunodeficiency virus which provides a novel mechanism of action called maturation inhibition. The company was founded by Graham Allaway in March 2005 and is headquartered in Watertown, MA.